QCG
DGX icon

Quadrant Capital Group’s Quest Diagnostics DGX Stock Holding History

Quadrant Capital Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$471K Buy
2,404
+131
+6% +$25.5K 0.01% 928
2025
Q4 		$394K Buy
2,273
+28
+1% +$5.1K 0.01% 1038
2025
Q3 		$428K Buy
2,245
+30
+1% +$5.32K 0.01% 958
2025
Q2 		$398K Buy
2,215
+36
+2% +$6.25K 0.01% 995
2025
Q1 		$369K Buy
2,179
+1,512
+227% +$248K 0.01% 943
2024
Q4 		$101K Buy
667
+75
+13% +$11.7K 0.01% 1046
2024
Q3 		$91.9K Buy
592
+19
+3% +$2.84K 0.01% 1116
2024
Q2 		$78.4K Buy
573
+174
+44% +$23.8K 0.01% 1153
2024
Q1 		$53.1K Sell
399
-41
-9% -$5.32K ﹤0.01% 1364
2023
Q4 		$60.7K Buy
440
+60
+16% +$7.89K 0.01% 1280
2023
Q3 		$46.3K Sell
380
-18
-5% -$2.4K ﹤0.01% 1306
2023
Q2 		$55.9K Sell
398
-5
-1% -$689 0.01% 1204
2023
Q1 		$57K Sell
403
-159
-28% -$22.7K 0.01% 1158
2022
Q4 		$87.9K Buy
562
+154
+38% +$22.1K 0.01% 855
2022
Q3 		$50K Sell
408
-86
-17% -$11.3K 0.01% 1044
2022
Q2 		$66K Buy
494
+72
+17% +$9.81K 0.01% 785
2022
Q1 		$57K Sell
422
-71
-14% -$9.9K 0.01% 866
2021
Q4 		$85K Buy
493
+81
+20% +$12.3K 0.01% 720
2021
Q3 		$60K Buy
412
+34
+9% +$4.97K 0.01% 791
2021
Q2 		$50K Sell
378
-1
-0.3% -$131 0.01% 843
2021
Q1 		$49K Buy
379
+114
+43% +$14K 0.01% 816
2020
Q4 		$32K Buy
265
+15
+6% +$1.83K 0.01% 901
2020
Q3 		$29K Sell
250
-170
-40% -$20.1K 0.01% 822
2020
Q2 		$48K Sell
420
-456
-52% -$48.4K 0.01% 731
2020
Q1 		$72K Buy
876
+29
+3% +$3K 0.01% 712
2019
Q4 		$84K Buy
847
+58
+7% +$6.05K 0.01% 1071
2019
Q3 		$80K Buy
789
+5
+0.6% +$513 0.01% 998
2019
Q2 		$73K Buy
784
+88
+13% +$8.46K 0.01% 1027
2019
Q1 		$60K Buy
696
+583
+516% +$50.5K 0.01% 1105
2018
Q4 		$8K Buy
113
+11
+11% +$1.03K ﹤0.01% 1461
2018
Q3 		$9K Hold
102
– – ﹤0.01% 1324
2018
Q2 		$10K Hold
102
– – ﹤0.01% 1253
2018
Q1 		$7K Hold
102
– – ﹤0.01% 1413
2017
Q4 		$7K Buy
102
+8
+9% +$758 ﹤0.01% 1333
2017
Q3 		$7K Hold
94
– – ﹤0.01% 1328
2017
Q2 		$6K Hold
94
– – ﹤0.01% 1265
2017
Q1 		$7K Buy
94
+28
+42% +$2.67K ﹤0.01% 1204
2016
Q4 		$4K Hold
66
– – ﹤0.01% 1295
2016
Q3 		$4K Hold
66
– – ﹤0.01% 1312
2016
Q2 		$4K Buy
66
+13
+25% +$990 ﹤0.01% 1271
2016
Q1 		$2K Buy
53
+46
+657% +$3.08K ﹤0.01% 1348
2015
Q4 		$0 Buy
+7
New +$471 ﹤0.01% 1597

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Quadrant Capital Group's DGX Position: Q1 2026 in Review

Quadrant Capital Group increased its Quest Diagnostics (DGX) stake by 5.8% in Q1 2026, buying an estimated $25.5K and bringing the position to 2,404 shares worth $471K. The position accounts for 0.01% of the portfolio, ranked #928.

Quadrant Capital Group first reported a position in DGX in Q4 2015 and has held it in 42 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Quadrant Capital Group held 2,404 shares of Quest Diagnostics worth $471K as of Q1 2026.
  • Quadrant Capital Group bought 131 Quest Diagnostics shares in Q1 2026, an estimated $25.5K.
  • Quest Diagnostics made up 0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #928 holding.
  • Quadrant Capital Group first reported a position in Quest Diagnostics in Q4 2015 and has held it in 42 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.